Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.

Duffy MJ, McDermott EW, Crown J.

Tumour Biol. 2018 May;40(5):1010428318776169. doi: 10.1177/1010428318776169. Review.

PMID:
29775157
2.

Towards optimized naphthalocyanines as sonochromes for photoacoustic imaging in vivo.

Duffy MJ, Planas O, Faust A, Vogl T, Hermann S, Schäfers M, Nonell S, Strassert CA.

Photoacoustics. 2018 Jan 11;9:49-61. doi: 10.1016/j.pacs.2017.12.001. eCollection 2018 Mar.

3.

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.

Duffy MJ, Synnott NC, Crown J.

Breast Cancer Res Treat. 2018 Jul;170(2):213-219. doi: 10.1007/s10549-018-4753-7. Epub 2018 Mar 21. Review.

PMID:
29564741
4.

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O'Donovan N, O'Connor D, Gallagher WM, Crown J, Fersht AR, Duffy MJ.

Cancer Lett. 2018 Feb 1;414:99-106. doi: 10.1016/j.canlet.2017.09.053. Epub 2017 Oct 22.

PMID:
29069577
5.

Prognostic and predictive biomarkers in breast cancer: Past, present and future.

Nicolini A, Ferrari P, Duffy MJ.

Semin Cancer Biol. 2017 Sep 4. pii: S1044-579X(17)30052-4. doi: 10.1016/j.semcancer.2017.08.010. [Epub ahead of print] Review.

PMID:
28882552
6.

Mutant p53 as a target for cancer treatment.

Duffy MJ, Synnott NC, Crown J.

Eur J Cancer. 2017 Sep;83:258-265. doi: 10.1016/j.ejca.2017.06.023. Epub 2017 Jul 28. Review.

PMID:
28756138
7.

Vitamin D analogues: Potential use in cancer treatment.

Duffy MJ, Murray A, Synnott NC, O'Donovan N, Crown J.

Crit Rev Oncol Hematol. 2017 Apr;112:190-197. doi: 10.1016/j.critrevonc.2017.02.015. Epub 2017 Feb 22. Review.

PMID:
28325259
8.

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).

Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F.

Eur J Cancer. 2017 Apr;75:284-298. doi: 10.1016/j.ejca.2017.01.017. Epub 2017 Feb 28. Review.

9.

Vitamin D receptor as a target for breast cancer therapy.

Murray A, Madden SF, Synnott NC, Klinger R, O'Connor D, O'Donovan N, Gallagher W, Crown J, Duffy MJ.

Endocr Relat Cancer. 2017 Apr;24(4):181-195. doi: 10.1530/ERC-16-0463. Epub 2017 Feb 17.

10.

Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy.

Duffy MJ, McDermott EW, Crown J.

Clin Chem. 2017 Apr;63(4):804-806. doi: 10.1373/clinchem.2016.267161. Epub 2017 Feb 10. No abstract available.

11.

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ.

Int J Cancer. 2017 Jan 1;140(1):234-246. doi: 10.1002/ijc.30425. Epub 2016 Sep 24.

12.

Validated biomarkers: The key to precision treatment in patients with breast cancer.

Duffy MJ, O'Donovan N, McDermott E, Crown J.

Breast. 2016 Oct;29:192-201. doi: 10.1016/j.breast.2016.07.009. Epub 2016 Aug 9. Review.

PMID:
27521224
13.

The ADAMs family of proteases as targets for the treatment of cancer.

Mullooly M, McGowan PM, Crown J, Duffy MJ.

Cancer Biol Ther. 2016 Aug 2;17(8):870-80. doi: 10.1080/15384047.2016.1177684. Epub 2016 Apr 26. Review.

14.

Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.

Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, Crown J, Duffy MJ.

Endocr Relat Cancer. 2016 Apr;23(4):323-34. doi: 10.1530/ERC-16-0068. Epub 2016 Mar 1.

15.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.

Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586.

16.

Use of Biomarkers in Screening for Cancer.

Duffy MJ.

Adv Exp Med Biol. 2015;867:27-39. doi: 10.1007/978-94-017-7215-0_3. Review.

PMID:
26530358
17.

Biomarkers in Breast Cancer: Where Are We and Where Are We Going?

Duffy MJ, Walsh S, McDermott EW, Crown J.

Adv Clin Chem. 2015;71:1-23. doi: 10.1016/bs.acc.2015.05.001. Epub 2015 Jun 23. Review.

PMID:
26411409
18.

ADAM10: a new player in breast cancer progression?

Mullooly M, McGowan PM, Kennedy SA, Madden SF, Crown J, O' Donovan N, Duffy MJ.

Br J Cancer. 2015 Sep 15;113(6):945-51. doi: 10.1038/bjc.2015.288. Epub 2015 Aug 18.

19.

A randomized clinical trial of ascorbic acid in open abdominal aortic aneurysm repair.

Duffy MJ, O'Kane CM, Stevenson M, Young IS, Harkin DW, Mullan BA, McAuley DF.

Intensive Care Med Exp. 2015 Dec;3(1):50. doi: 10.1186/s40635-015-0050-5. Epub 2015 Jul 1.

20.

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J, Duffy MJ.

Br J Cancer. 2015 Jun 9;112(12):1895-903. doi: 10.1038/bjc.2015.163. Epub 2015 May 26.

21.

Validation of new cancer biomarkers: a position statement from the European group on tumor markers.

Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM.

Clin Chem. 2015 Jun;61(6):809-20. doi: 10.1373/clinchem.2015.239863. Epub 2015 Apr 16. Review.

22.

Personalized treatment for patients with colorectal cancer: role of biomarkers.

Duffy MJ.

Biomark Med. 2015;9(4):337-47. doi: 10.2217/bmm.15.3. Review.

PMID:
25808438
23.

uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M.

Breast Cancer Res. 2014 Aug 22;16(4):428. doi: 10.1186/s13058-014-0428-4. Review.

24.

ADAM10 and ADAM17: New players in trastuzumab tesistance.

Duffy MJ, Crown J, Mullooly M.

Oncotarget. 2014 Nov 30;5(22):10963-4. No abstract available.

25.

p53 as a target for the treatment of cancer.

Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM.

Cancer Treat Rev. 2014 Dec;40(10):1153-60. doi: 10.1016/j.ctrv.2014.10.004. Review.

PMID:
25455730
26.
27.

Monitoring response to therapy in patients with cancer: is circulating DNA the answer?

Duffy MJ, Crown J.

Ann Transl Med. 2013 Oct;1(3):24. doi: 10.3978/j.issn.2305-5839.2013.07.02. No abstract available.

28.

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?

Gaule PB, Crown J, O'Donovan N, Duffy MJ.

Expert Opin Ther Targets. 2014 Sep;18(9):999-1009. doi: 10.1517/14728222.2014.938050. Epub 2014 Aug 1. Review.

PMID:
25084805
29.

Precision treatment for cancer: role of prognostic and predictive markers.

Duffy MJ, Crown J.

Crit Rev Clin Lab Sci. 2014 Feb;51(1):30-45. doi: 10.3109/10408363.2013.865700. Epub 2014 Jan 16. Review. Erratum in: Crit Rev Clin Lab Sci. 2014 Aug;51(4):248.

PMID:
24432844
30.

ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis.

Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg Á, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE.

EMBO Mol Med. 2014 Feb;6(2):278-94. doi: 10.1002/emmm.201303373. Epub 2013 Dec 27.

31.

Investigation of molecular alterations of AKT-3 in triple-negative breast cancer.

O'Hurley G, Daly E, O'Grady A, Cummins R, Quinn C, Flanagan L, Pierce A, Fan Y, Lynn MA, Rafferty M, Fitzgerald D, Pontén F, Duffy MJ, Jirström K, Kay EW, Gallagher WM.

Histopathology. 2014 Apr;64(5):660-70. doi: 10.1111/his.12313. Epub 2013 Dec 12.

PMID:
24138071
32.

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A.

Oncotarget. 2013 Oct;4(10):1592-605.

33.

Exploring the glycosylation of serum CA125.

Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM.

Int J Mol Sci. 2013 Jul 26;14(8):15636-54. doi: 10.3390/ijms140815636.

34.

Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.

Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C.

Int J Cancer. 2014 Jun 1;134(11):2513-22. doi: 10.1002/ijc.28384. Epub 2013 Aug 27. Review.

35.

Fragmentation of neutral amino acids and small peptides by intense, femtosecond laser pulses.

Duffy MJ, Kelly O, Calvert CR, King RB, Belshaw L, Kelly TJ, Costello JT, Timson DJ, Bryan WA, Kierspel T, Turcu IC, Cacho CM, Springate E, Williams ID, Greenwood JB.

J Am Soc Mass Spectrom. 2013 Sep;24(9):1366-75. doi: 10.1007/s13361-013-0653-6. Epub 2013 Jul 2.

PMID:
23817831
36.

Effect of simvastatin on physiological and biological outcomes in patients undergoing esophagectomy: a randomized placebo-controlled trial.

Shyamsundar M, McAuley DF, Shields MO, MacSweeney R, Duffy MJ, Johnston JR, McGuigan J, Backman JT, Calfee CS, Matthay MM, Griffiths MJ, McDowell C, Elborn SJ, OʼKane CM.

Ann Surg. 2014 Jan;259(1):26-31. doi: 10.1097/SLA.0b013e31829d686b.

PMID:
23817506
37.

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.

Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ.

Cancer Biol Ther. 2013 Jun;14(6):537-45. doi: 10.4161/cbt.24349.

38.

Companion biomarkers: paving the pathway to personalized treatment for cancer.

Duffy MJ, Crown J.

Clin Chem. 2013 Oct;59(10):1447-56. doi: 10.1373/clinchem.2012.200477. Epub 2013 May 8. Review.

39.

The war on cancer: are we winning?

Duffy MJ.

Tumour Biol. 2013 Jun;34(3):1275-84. doi: 10.1007/s13277-013-0759-2. Epub 2013 Apr 9. Review.

PMID:
23568704
40.

Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.

O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM.

BMC Cancer. 2013 Apr 2;13:175. doi: 10.1186/1471-2407-13-175.

41.

Observation of Ultrafast Charge Migration in an Amino Acid.

Belshaw L, Calegari F, Duffy MJ, Trabattoni A, Poletto L, Nisoli M, Greenwood JB.

J Phys Chem Lett. 2012 Dec 20;3(24):3751-4. doi: 10.1021/jz3016028. Epub 2012 Dec 5.

PMID:
26291106
42.

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.

Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N.

Breast Cancer Res Treat. 2012 Dec;136(3):717-27. doi: 10.1007/s10549-012-2260-9. Epub 2012 Nov 2. Erratum in: Breast Cancer Res Treat. 2014 Dec;148(3):697.

PMID:
23117852
43.

Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM.

Clin Chem. 2013 Jan;59(1):52-9. doi: 10.1373/clinchem.2011.180778. Epub 2012 Oct 3.

44.

ADAM-17: a novel therapeutic target for triple negative breast cancer.

McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O'Donovan N, Duffy MJ.

Ann Oncol. 2013 Feb;24(2):362-9. doi: 10.1093/annonc/mds279. Epub 2012 Sep 11. Erratum in: Ann Oncol. 2013 Aug;24(8):2199.

PMID:
22967992
45.

Tumor markers in clinical practice: a review focusing on common solid cancers.

Duffy MJ.

Med Princ Pract. 2013;22(1):4-11. doi: 10.1159/000338393. Epub 2012 May 15. Review.

46.

Targeted therapy for triple-negative breast cancer: where are we?

Duffy MJ, McGowan PM, Crown J.

Int J Cancer. 2012 Dec 1;131(11):2471-7. doi: 10.1002/ijc.27632. Epub 2012 Jun 7. Review.

47.

LIAD-fs scheme for studies of ultrafast laser interactions with gas phase biomolecules.

Calvert CR, Belshaw L, Duffy MJ, Kelly O, King RB, Smyth AG, Kelly TJ, Costello JT, Timson DJ, Bryan WA, Kierspel T, Rice P, Turcu IC, Cacho CM, Springate E, Williams ID, Greenwood JB.

Phys Chem Chem Phys. 2012 May 14;14(18):6289-97. doi: 10.1039/c2cp23840c. Epub 2012 Feb 9.

PMID:
22322861
48.

The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer.

Brennan DJ, O'Connor DP, Laursen H, McGee SF, McCarthy S, Zagozdzon R, Rexhepaj E, Culhane AC, Martin FM, Duffy MJ, Landberg G, Ryden L, Hewitt SM, Kuhar MJ, Bernards R, Millikan RC, Crown JP, Jirström K, Gallagher WM.

Oncogene. 2012 Jul 26;31(30):3483-94. doi: 10.1038/onc.2011.519. Epub 2011 Dec 5.

49.

Femtosecond lasers for mass spectrometry: proposed application to catalytic hydrogenation of butadiene.

Kelly O, Duffy MJ, King RB, Belshaw L, Williams ID, Sá J, Calvert CR, Greenwood JB.

Analyst. 2012 Jan 7;137(1):64-9. doi: 10.1039/c1an15706j. Epub 2011 Nov 9.

PMID:
22068546
50.

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.

Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J.

Ann Oncol. 2012 Jul;23(7):1788-95. doi: 10.1093/annonc/mdr484. Epub 2011 Nov 5. Erratum in: Ann Oncol. 2013 Jan;24(1):268.

PMID:
22056974

Supplemental Content

Loading ...
Support Center